Hanna Sanoff Archives - UNC Lineberger Comprehensive Cancer Center

June 22, 2025

Oncology: FDA Limits Pembrolizumab/Nivolumab in PD-L1–Low Gastric Cancer Indications

Human colon cancer cells with the cell nuclei stained red and the protein E-cadherin stained green. E-cadherin is a cell adhesion molecule and its loss signals a process known as the epithelial-mesenchymal transition in which cells acquire the ability to migrate and become invasive.

UNC Lineberger researchers have demonstrated that combining two immunotherapy drugs with a targeted therapy drug proved effective in treating the most common form of metastatic colorectal cancer.

Tag: Hanna Sanoff

Oncology: FDA Limits Pembrolizumab/Nivolumab in PD-L1–Low Gastric Cancer Indications

WRAL: Medicine spares cancer patients from grisly surgeries and harsh therapies

Immunotherapy and targeted therapy combination proves effective against metastatic colorectal cancer

ABC11: UNC doctor speaks on effects of diet on health as younger adults are diagnosed with colon cancer

Becker’s Hospital Review: 761 exceptional women in oncology, per Castle Connolly

WNDU: Medical Moment: A better delivery system for chemotherapy

Ivanoe Medical Breakthroughs: New Targeted Chemo Kills Colorectal Cancer

Morning Call: Your View: If Congress imposes price controls on drugs, patients will suffer

Daily Wealth: The ‘Platinum Age of Health Care’ Is Turning the Tables

Cancer Letter: In early results “unprecedented in rectal cancer,” 14/14 patients show clinical complete response to dostarlimab